Status:
UNKNOWN
Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
PHASE3
Brief Summary
Gemcitabine plus carboplatin in recurrent or metastatic breast cancer is a recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. gemcitabine in combination with capecitabine is...
Detailed Description
A multicenter randomized phase Ⅲ clinical trial of gemcitabine in combination with capecitabine versus gemcitabine plus carboplatin as first-line treatment in triple-negative recurrent or metastatic b...
Eligibility Criteria
Inclusion
- Female
- 18-70 years old
- ECOG 0-1
- Expected lifetime more than 12 weeks
Exclusion
- Pregnancy
- Brain Metastasis,
- Severe Infection
Key Trial Info
Start Date :
December 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT02207335
Start Date
December 1 2013
End Date
December 1 2016
Last Update
December 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300061